



- (51) **International Patent Classification:**
A61K 47/68 (2017.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/IB2021/052889
- (22) **International Filing Date:**
07 April 2021 (07.04.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/006,998 08 April 2020 (08.04.2020) US
63/036,020 08 June 2020 (08.06.2020) US
- (71) **Applicant:** JANSSEN BIOTECH, INC. [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US).
- (72) **Inventors:** EDAVETAL, Suzanne; 941 W Hawthorn APT 5, San Diego, California 92101 (US). SINGH, Sanjaya; 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477 (US). DOMINGO, Derrick; 3210 Merryfield Row, San Diego, California 92121 (US). WILKINSON, Deepti; 13660 Mango Drive, Del Mar, California 92014 (US). CEJUDO-MARTIN, Pilar; 3210 Merryfield Row, San Diego, California 92121 (US). JAIPRASART, Pharavee; 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477 (US). GEIST, Brian; 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477 (US).
- (74) **Agent:** SHIRTZ, Joseph F. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) **Title:** COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY




FIG. 1

(57) **Abstract:** Monoclonal anti-TfR antibodies and antigen-binding fragments thereof for delivering an agent to the brain of a subject in need thereof are described. Also described are conjugates and fusion constructs containing the anti-TfR antibody or antigen-binding fragment thereof coupled to a therapeutic or diagnostic agent, such as a second antibody and antigen-binding fragment thereof, for treating or detecting a neurological disorder and/or delivering a therapeutic or diagnostic agent across the blood-brain barrier. Also described are nucleic acids encoding the antibodies, conjugates and fusion constructs and related recombinant host cells.

[Continued on next page]



Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*